Devices › Device types
FDA product code PAG · class 2 · General, Plastic Surgery
Mesh, surgical, non-synthetic, urogynecologic, for stress urinary incontinence, retropubic or transobturator: medical device reports filed with FDA
756 reports carry this product code, 2008–2023; 8 brands with a page.
- 756
- reports with this product code
- 0% of all MAUDE reports
- 0
- reports, 12 months to August 2026
- 0 in the 12 months before
- 0.3%
- classified as malfunction
- 62.3% across all reports
- 0%
- classified as death, as reported
- 0.9% across all reports
Product code PAG is FDA's classification for "Mesh, surgical, non-synthetic, urogynecologic, for stress urinary incontinence, retropubic or transobturator" (general, Plastic Surgery panel), a class 2 device. 756 medical device reports carry this product code, 0% of the MAUDE database, from January 2008 to February 2023.
0 reports arrived in the 12 months to August 2026, and none in the 12 months before. FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases. The event types recorded are injury (99.5%) and malfunction (0.3%). 8 brand names with a page on this site carry this code; the brands table is ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Brands with this product code
| Brand | Reports | Latest 12 months | Classified as death | Classified as malfunction |
|---|---|---|---|---|
| Unk - Unspecified By The Complainant | 51 | 0 | 0% | 0% |
| Unknown - Unspecified By The Complainant | 51 | 0 | 0% | 0% |
| Pelvilace Biourethral Support System | 40 | 0 | 0.3% | 0.7% |
| Pelvilace To Biourethral Support System | 23 | 0 | 0% | 0% |
| Unspecified By The Complainant | 21 | 0 | 0% | 0% |
| Biodesign 4-Layer Tissue Graft | 11 | 0 | 0% | 0% |
| Unspecified By Complainant | 4 | 0 | 0% | 0% |
| Pelvicol Acellular Collagen Matrix | 1 | 0 | 0% | 0% |
Ordered by report count for navigation only. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data."
Manufacturers named
| Manufacturer (as written on reports) | Reports | Share |
|---|---|---|
| Cook Biotech | 401 | 53% |
| Tissue Science Laboratories | 49 | 6.5% |
| C R Bard Covington -1018233 | 31 | 4.1% |
Reports by month, five years
FDA releases MAUDE data monthly; reports can arrive months after an event, so the newest months grow in later releases.
Event type and report source
Event type
Who filed
Grey bar: all 26,136,888 MAUDE reports.
Device problems coded
| Device problem (FDA code) | Reports | Share |
|---|---|---|
| Insufficient device problem information | 496 | 65.6% |
| Device operates differently than expectedthe device behaved unexpectedly | 19 | 2.5% |
| Unexpected therapeutic results | 6 | 0.8% |
| Patient-device incompatibilitythe device did not suit the patient | 4 | 0.5% |
| Breakthe device broke | 3 | 0.4% |
| Material erosion | 3 | 0.4% |
| Material protrusion/extrusion | 3 | 0.4% |
| Extrusion | 2 | 0.3% |
| Migration or expulsion of device | 2 | 0.3% |
| Defective component | 1 | 0.1% |
| Difficult to removethe device was hard to remove | 1 | 0.1% |
| Fluid/blood leak | 1 | 0.1% |
| Invalid sensing | 1 | 0.1% |
| Malposition of device | 1 | 0.1% |
| Patient device interaction problem | 1 | 0.1% |
| Suture line disruption | 1 | 0.1% |
| Therapeutic or diagnostic output failure | 1 | 0.1% |
Questions about mesh, surgical, non-synthetic, urogynecologic, for stress urinary incontinence, retropubic or transobturator reports
What is product code PAG?
FDA's classification code for "Mesh, surgical, non-synthetic, urogynecologic, for stress urinary incontinence, retropubic or transobturator", class 2, reviewed by the general, Plastic Surgery panel. Every device report carries the product code of the device involved.
How many reports carry this code?
756 reports through August 2026, 0 of them in the latest 12 months.
Which brands appear most often?
Unk - Unspecified By The Complainant (51), Unknown - Unspecified By The Complainant (51), Pelvilace Biourethral Support System (40), Pelvilace To Biourethral Support System (23) and Unspecified By The Complainant (21). Widely used products collect more reports because more people use them.
Can the brands table be used to rank the devices?
No. FDA states that "MDR data alone cannot be used to establish rates of events, evaluate a change in event rates over time or compare event rates between devices. The number of reports cannot be interpreted or used in isolation to reach conclusions about the existence, severity, or frequency of problems associated with devices." It adds that the reporting system "has limitations, including the potential submission of incomplete, inaccurate, untimely, unverified, or biased data." Brands differ in how many are in use, how long they have been sold and how reports are collected.
Where this comes from. Counts are built from the openFDA Device Adverse Event (MAUDE) bulk export released 28 Sep 2026, which holds reports FDA received through 31 Aug 2026. Brand, generic and manufacturer names are as written on the reports; product code names come from FDA's device classification. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.
Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.